Spero Therapeutics
184 articles about Spero Therapeutics
-
Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development
7/16/2018
Inter-agency collaboration among BARDA, DTRA, USAMRIID and Spero to fund further clinical development of product candidate SPR994
-
Spero Therapeutics Announces Pricing of Securities Offering
7/13/2018
Spero Therapeutics, Inc. announced the pricing of an underwritten public offering of 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock.
-
Spero Therapeutics Announces Proposed Offering of Common Stock
7/9/2018
Spero Therapeutics, Inc. announced that it has commenced an underwritten public offering of 4,500,000 shares of its common stock.
-
Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994
7/9/2018
Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending doses
-
Spero Announces Appointment of David P. Southwell to its Board of Directors
2/1/2018
Broad leadership and financial expertise adds to our board’s breadth of talent and background.
-
Motif Bio PLC, Spero Therapeutics and Vical Incorporated Join Antimicrobials Working Group
1/30/2018
The Antimicrobials Working Group announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations.
-
Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer
1/4/2018
Dr. Melnick to lead clinical team as Spero prepares to enter late-stage clinical trials.
-
Spero Therapeutics Announces 3Q17 Operating Results and Pipeline Update
12/15/2017
The Company reported a net loss of $(12.1) million, or basic and diluted net loss per common share of $(36.02), for the third quarter of 2017.
-
A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics.
-
Spero Therapeutics Announces Underwriters’ Option Exercise
11/13/2017
Spero’s common stock began trading on The Nasdaq Global Select Market on November 2, 2017 under the symbol “SPRO”.
-
Spero Therapeutics Announces Closing of Initial Public Offering
11/7/2017
The company has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of its common stock at the initial public offering price.
-
Spero Therapeutics Announces Pricing of Initial Public Offering
11/2/2017
Spero Therapeutics, Inc.’s shares are expected to begin trading on The Nasdaq Global Select Market on November 2, 2017 under the symbol “SPRO.”
-
Spero Therapeutics Launches Initial Public Offering
10/23/2017
Spero has also granted the underwriters a 30-day option to purchase an additional 750,000 shares of its common stock.
-
Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994
10/20/2017
Spero plans for a rapid development approach with SPR994.
-
Spero Licenses Exclusive Rights To SPR994, A Novel Oral Carbapenem Being Studied For Use In Adults
10/10/2017
-
Massachusetts' Spero Files for $86 Million IPO
10/9/2017
-
Spero Announces Positive Phase I Clinical Data From Potentiator Platform
10/3/2017
-
Spero Announces Appointment Of Frank Thomas To Its Board Of Directors And Promotions Within Leadership Team
9/6/2017
-
Spero Appoints Joel Sendek As Chief Financial Officer
5/22/2017
-
Spero Receives Grant From NIH To Explore Novel Treatment Combinations For Tuberculosis
5/4/2017